Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
Good momentum in commercial CDMO business
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection
Subscribe To Our Newsletter & Stay Updated